Publications
Selected publications
1. Oncolytic virotherapy for urological cancers
Zahid Delwar*, Kaixin Zhang*，Paul S. Rennie, William Jia.
Nature Reviews Urology, 2016 Jun;13(6):334-5
2. Intravesical treatment of advanced urothelial bladder cancers with oncolytic HSV-1 synergistically regulated by microRNAs
Kai-xin Zhang*, Yoshiyuki Matsui*, Cleo Lee, Ogawa Osamu, Lisa Skinner, Jun Wang, Alan So, Paul S. Rennie, William Jia.
Gene therapy. 2016 Feb 23. doi: 10.1038/gt.2016.18
3. Targeted oncolytic herpes simplex viruses for aggressive cancers.
Wong J, Lee C, Zhang K, Rennie PS, Jia W.
Current Pharmcetical Biotechnology. 2012 Jul;13 (9):1786-94.
4. Targeting trastuzumab-resistant breast cancer cells with a lentivirus engineered to bind antibodies that recognize HER-2.
Zhang KX, Kim C, Chow E, Chen IS, Jia W, Rennie PS.
Breast Cancer Research and Treatment. 2010 Mar 16. PMID: 20232140
5. Bioengineered viral vectors for targeting and killing prostate cancer cells
Kai-xin Zhang, William Jia and Paul S. Rennie
Bioengineered Bugs Volume 1, Issue 2 March/April 2010 Landes Bioscience
6. Down-regulation of type I interferon receptor sensitizes bladder cancer cells to vesicular stomatitis virus-induced cell death.
Zhang KX, Matsui Y, Hadaschik BA, Lee C, Jia W, Bell JC, Fazli L, So AI, Rennie PS.
International Journal of Cancer. 2009 Dec 2.
7. Lentiviruses with trastuzumab bound to their envelopes can target and kill prostate cancer cells.
Zhang KX, Moussavi M, Kim C, Chow E, Chen IS, Fazli L, Jia W, Rennie PS.
Cancer Gene Therapy. 2009 Nov;16 (11):820-31.
8. Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer
Hadaschik BA*, Zhang K*, So AI, Fazli L, Jia W, Bell JC, Gleave ME, Rennie PS.
Cancer Research. 2008 Jun 15;68 (12):4506-10. *Contributed equally.
9. Oncolytic vesicular stomatitis viruses as intravesical agents against non-muscle-invasive bladder cancer
Hadaschik BA, Zhang K, So AI, Bell JC, Thüroff JW, Rennie PS, Gleave ME.
Urologie A. 2008 Sep; 47 (9):1145-51
10. A Glu-urea-Lys ligand-conjugated lipid nanoparticle/siRNA system inhibits androgen receptor expression in vivo
Justin B Lee*, Kaixin Zhang*, Yuen Yi C Tam, Joslyn Quick, Ying K Tam, Paulo J C Lin, Sam Chen, Yan Liu, Jayaprakash K Nair, Ivan Zlatev, Kallanthottathil G. Rajeev, Muthiah Manoharan, Paul S Rennie, and Pieter R Cullis.
Molecular Therapy- Nucleic Acids, 2016;5:e348.
11. Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo
Lee JB*, Zhang K*, Tam YY, Tam YK, Belliveau NM, Sung VY, Lin PJ, LeBlanc E, Ciufolini MA, Rennie PS, Cullis PR
International Journal of Cancer. Volume 131, Issue 5, E781–790, Sept 2012
12. Multiple aspects of the phenotype of mammary epithelial cells transformed by expression of activated M-Ras depend on an autocrine mechanism mediated by hepatocyte-growth factor/scatter factor
Kai-Xin Zhang, Katherine R. Ward, John W. Schrader
Molecular Cancer Research 2004, April, 2(4) 24255
13. Expression of activated M-Ras in a murine mammary epithelial cell line induces epithelial-mesenchymal transition and tumorigenesis
KR.Ward, KX Zhang, A.Sommari, C.Roskelly, JW.Schrader
Oncogene (2003) 00, 1-10